• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Catalent Expands Durham, North Carolina, Operations

Catalent, a leading global development and manufacturing partner to the pharmaceutical, biopharmaceutical and consumer health industries, will establish a new biologics analytical center of excellence in Durham, North Carolina. The roughly $40 million project is expected to create more than 200 jobs over the next five years.

The company's BioAnalytics division offers comprehensive standalone analytical development and testing for different treatments including cell and gene therapies. The investment will expand Catalent’s support of large molecule development and manufacturing growth.

“Catalent is committed to the continuous growth and expansion of its analytical capabilities,” said Jeremie Trochu, Division Head for BioAnalytics at Catalent. “By establishing significant additional capacity here on the East Coast, we can offer our customers greater flexibility and expanded support services across the biologics and advanced modalities development pipeline.”

This project from Catalent will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee. Over the course of the eight-year term of the grant, the project is estimated to grow the state’s economy by more than $378 million. Using a formula that takes into account the new tax revenues generated by the 201 new jobs, the JDIG agreement authorizes the potential reimbursement to the company of up to $805,500 spread over eight years.

Payments for all JDIGs only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets. JDIG projects result in positive net tax revenue to the state treasury, even after taking into consideration the grant’s reimbursement payments to a given company.

“North Carolina is a leading life sciences cluster with a 10 percent increase in pharmaceutical manufacturing businesses over the past five years,” noted N.C. Commerce Secretary Machelle Baker Sanders. “With the largest pharmaceutical manufacturing workforce in the southeastern United States, Tier 1 research network, and a strong transportation system for global distribution, we believe Catalent will be successful doing business here.”

Because Catalent is located in Durham County, classified by the state’s economic tier system as Tier 3, the company’s JDIG agreement also calls for moving $268,000 into the state’s Industrial Development Fund – Utility Account. The Utility Account helps rural communities across the state finance necessary infrastructure upgrades to attract future business.

“Catalent is an industry leader in bringing important and life-saving drugs to market, and their announcement of 200-plus new jobs right here in Durham County adds a key piece to our biotechnology ecosystem,” Durham County Economic Development Manager Matthew Filter added. “We also greatly appreciate the opportunity to help them partner with local institutions to hire local talent and grow the local life sciences workforce.”

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians.

Partnering with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina (EDPNC) on this project were the North Carolina General Assembly, the North Carolina Community College System, the North Carolina Biotechnology Center, Durham County and the Greater Durham Chamber of Commerce.

Exclusive Research